Every one of those 1 sits in a single category, pharma. Raymond James Financial is most often covered alongside B. Riley Financial, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Raymond James Financial, all published on August 4, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Raymond James Financial
Every one of those 1 sits in a single category, pharma. Raymond James Financial is most often covered alongside B. Riley Financial, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Raymond James Financial, all published on August 4, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Raymond James Financial. Shared-story counts are live from our verified record — not editorial picks.
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.